Shares of Theravance Biopharma TBPH were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 21.37% over the past year to ($0.92), which beat the estimate of ($1.02).
Revenue of $18,730,000 declined by 36.51% from the same period last year, which missed the estimate of $20,850,000.
Outlook
Theravance Biopharma Sees Operating Expenses For R&D At $195M-$225M
How To Listen To The Conference Call
Date: Feb 23, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/8r4422vu
Technicals
Company's 52-week high was at $31.35
Company's 52-week low was at $14.48
Price action over last quarter: Up 5.12%
Company Overview
Theravance Biopharma is a diversified biotechnology company that creates medicines to treat serious illnesses. The company's research and development are concentrated primarily on four therapeutic areas-infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease. Its commercial infrastructure is focused primarily on the acute care setting. The company uses strategic collaboration with other industry players. Theravance generates the majority of its revenue in the U.S. and Europe, followed by Asia.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
